Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 4, July-August, p. 585–591

Publication type: review article

Language: English

Hepcidin and Its Role in Inflammatory Bowel Disease

Hepcydyna i jej rola w nieswoistych zapaleniach jelit

Robert Dudkowiak1,A,B,C,D, Katarzyna Neubauer2,A,B,C,D,E,F, Elżbieta Poniewierka1,A,E,F

1 Division of Dietetics, Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wrocław, Poland

2 Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wrocław, Poland

Abstract

Abstract
Anemia is one of the most common extraintestinal symptoms of inflammatory bowel disease (IBD). The pathophys- iology of anemia in IBD is complex. It may be developed in the course of inflammation, intestinal bleeding or dis- orders of iron absorption. Hepcidin, discovered in the year 2000, is an endogenous peptide responsible for iron homeostasis. Recent data suggests that hepcidin is a major mediator of anemia and plays a central role in iron homeostasis and metabolism. This paper presents information about hepcidin structure and function, mecha- nisms of the regulation of the synthesis and current data about the role of this hormone in IBD-related anemia. Assessment of hepcidin levels in patients with IBD may become a key element in the treatment of anemia in the near future (Adv Clin Exp Med 2013, 22, 4, 585–591).
 

Streszczenie

Niedokrwistość to jeden z najczęstszych pozajelitowych objawów nieswoistych zapaleń jelit (n.z.j.). Patomechanizm niedokrwistości w n.z.j. jest złożony i może być związany ze stanem zapalnym, krwawieniem do światła przewodu pokarmowego lub zaburzeniami wchłaniania żelaza. Hepcydyna, odkryta w 2000 r., jest endogennym peptydem odpowiedzialnym za homeostazę żelaza. Obecnie uważa się, że hepcydyna jest głównym mediatorem niedokrwistości i odgrywa kluczową rolę w metabolizmie żelaza w ustroju. W artykule autorzy przedstawiają informacje o strukturze i funkcji hepcydyny, mechanizmach regulujących jej syntezę oraz bieżące doniesienia na temat roli tego hormonu w rozwoju niedokrwistości w n.z.j. Ocena stężenia hepcydyny u pacjentów z n.z.j. może stać się w najbliższej przyszłości kluczowym elementem w podejmowaniu decyzji terapeutycznych i leczeniu niedokrwistości.

Key words

hepcidin, inflammatory bowel disease, anemia.

Słowa kluczowe

hepcydyna, nieswoiste zapalenia jelit, niedokrwistość.

References (34)

  1. Vagianos K, Bector S, McConnell J, Bernstein CN: Nutrition Assessment of Patients With Inflammatory Bowel Disease. JPEN J Parenter Enteral Nutr 2007, 31, 311–319.
  2. Semrin G, Fishman DS, Bousvaros A, Zholudev A, Saunders AC, Correia CE, Nemeth E, Grand RJ, Weinstein DA: Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 2006, 12, 1101–1106.
  3. Wilson A, Reyes E, Ofman J: Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004, 116, 44S–49S.
  4. Gasche C: Anemia in IBD: the overlooked villain. Inflamm Bowel Dis 2000, 6, 142–150.
  5. Wells CW, Lewis S, Barton JR, Corbett S: Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006, 12, 123–130.
  6. Radwan P, Radwan-Kwiatek K, Skrzydło-Radomańska B, Rydzewska G: Niedokrwistość w nieswoistych zapaleniach jelit – etiopatogeneza, rozpoznawanie i leczenie. Prz Gastroenterol 2010, 6, 315–320.
  7. Krause A, Neitz S, Magert HJ Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K: LEAP-1, a novel highly disulfide-bonded peptide, exhibits antimicrobial activity. FEBS Lett 2000, 480, 147–150.
  8. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001, 276, 7806–7810.
  9. Atanasiu V, Manolescu B, Stoian I: Hepcidin – central regulator of iron metabolism. Eur J Haematol 2007, 78, 1–10.
  10. Nemeth E: Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010, 2010, 750643. Epub 2009 Dec 24.
  11. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC, Koliaraki V, Mamalaki A, Olbina G, Tomosugi N, Tselepis C, Ward DG, Ganz T, Hendriks JC, Swinkels DW: Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009, 94, 1748–1752.
  12. Kemna EH, Tjalsma H, Podust VN, Swinkels DW: Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 2007, 53, 620–628.
  13. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306, 2090–2093.
  14. Ganz T: Iron homeostasis: fitting the puzzle pieces together. Cell Metab 2008, 7, 288–290.
  15. Dallalio G, Law E, Means RTJr: Hepcidin inhibits in vivo erythroid colony formation at reduced erythropoietin concentrations. Blood 2006, 107, 2702–2704.
  16. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102, 783–788.
  17. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002, 110, 1037–1044.
  18. Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, Knutson MD, Pietrangelo A, Vukicevic S, Lin HY, Babitt JL: BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009, 41, 482–487.
  19. An P, Wu Q, Wang H, Guan Y, Mu M, Liao Y, Zhou D, Song P, Wang C, Meng L, Man Q, Li L, Zhang J, Wang F: TMPRSS6, but not TF, TFR2 or BMP2 variants are associated with increased risk of iron-deficiency anemia. Hum Mol Genet 2012, 21, 2124–2131.
  20. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, Enns CA: Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009, 9, 217–227.
  21. Ashrafian H: Hepcidin: the missing link between hemochromatosis and infections. Infect Immun 2003, 71, 6693–6700.
  22. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS: Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007, 117, 1926–1932.
  23. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005, 352, 1011–1023.
  24. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113, 1271–1276.
  25. Pastorelli L, Testa C, Rigolini R, Giubbilini R, Spina L, Tontini G, Munizio N, De Salvo C, Rampoldi B, Costa E, Vecchi M: Anti TNF therapy improves stored body iron serum markers in inflammatory bowel disease patients. Gastroenterology 2011, 140, Suppl. 1, S278.
  26. Bergamaschi G, Di Sabatino A, Albertini R, Ardizzone S, Biancheri P, Bonetti E, Cassinotti A, Cazzola P, Markopoulos K, Massari A, Rosti V, Porro GB, Corazza GR: Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica 2010, 95, 199–205.
  27. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005, 106, 1864–1866.
  28. Semrin G, Fishman DS, Bousvaros A, Zholudev A, Saunders AC, Correia CE, Nemeth E, Grand RJ, Weinstein DA: Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 2006, 12, 1101–1106.
  29. Arnold J, Sangwaiya A, Bhatkal B, Geoghegan F, Busbridge M: Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis. Eur J Gastroenterol Hepatol 2009, 21, 425–429.
  30. Oustamanolakis P, Koutroubakis IE, Messaritakis I, Malliaraki N, Sfiridaki A, Kouroumalis EA: Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011, 23, 262–268.
  31. Nagy J, Lakner L, Poór VS, Pandur E, Mózsik G, Miseta A, Sipos K: Serum prohepcidin levels in chronic inflammatory bowel diseases. J Crohns Colitis 2010, 4, 649–653.
  32. Kaya Z, Yildiz E, Gursel T, Albayrak M, Kocak U, Karadeniz C, Dalgiç B: Serum Prohepcidin levels in children with solid tumors, inflammatory bowel disease and iron deficiency anaemia. J Trop Pediatr 2010, 57, 120–125.
  33. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G: Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammationinduced anemia. Blood 2010, 115, 3616–3624.
  34. Wang L, Trebicka E, Fu Y, Ellenbogen S, Hong CC, Babitt JL, Lin HY, Cherayil BJ: The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18, 112–119.
© Wroclaw Medical University